There are 2789 resources available
294P - Cell-free DNA (cfDNA) workflow for the risk definition of dose-limiting and recurrent neutropenia in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC)
Presenter: Lorenza Palmero
Session: ePoster Display
295P - Clinical characterization and outcome of a HER2-low metastatic breast cancer (mBC) cohort receiving first-line treatment (1L) with ET +/- CDK 4/6 inhibitor (CDKi)
Presenter: Lucia Bortot
Session: ePoster Display
296P - Recapitulation of organ-specific breast cancer metastasis using an engineered multi-tissue platform
Presenter: Alan Chramiec
Session: ePoster Display
297P - Transcriptomic modification induced by the first cycle of neoadjuvant chemotherapy impacts response to treatment in triple-negative breast cancer (TNBC)
Presenter: Isabelle Desmoulins
Session: ePoster Display
298P - Clinical implication of gene alterations revealed by comprehensive genomic profiling and clonal hematopoiesis in relapsed breast cancer patients
Presenter: Lanxin Zhang
Session: ePoster Display
299P - MicroRNAs-449 regulate doxorubicin response through ACSL4 modulation in TNBC
Presenter: sandra Torres Ruiz
Session: ePoster Display
300P - Mutational patterns across breast cancer subtypes during metastatic disease progression
Presenter: Hao Liao
Session: ePoster Display
301P - Integrins in different subsets of circulating tumor cells in breast cancer
Presenter: Evgeniya Grigoryeva
Session: ePoster Display
302P - Clinical implication of tissue re-biopsy in metastatic breast cancer (MBC) patients: A single centre retrospective analysis
Presenter: Francesca Carlino
Session: ePoster Display
303P - Role of ddPCR in the diagnosis of PIK3CA in breast cancer
Presenter: Zhanet Grudeva-Popova
Session: ePoster Display